Barbital

Barbital

SCHEMBL2128368

CCC1(CC)C(=O)NC(=O)NC1=O.Nc1nc(N)nc(N(c2ccc(Br)cc2)c2ccc(Br)cc2)n1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.44
▸ MAPT P10636 2/20 0.39
▸ ALDH1A1 P00352 3/20 0.37
▸ NPC1 O15118 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ TSHR P16473 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MMP14 P50281 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ PRNP P04156 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Barbital SCHEMBL1650226 0.76 AGPAT2 (0.43) LMNAMAPTALDH1A1NPC1JAK2
Barbital SCHEMBL43818 0.66 LMNA (1.00) LMNAALDH1A1TSHRSMN1; SMN2HSD17B10
Barbital SCHEMBL3859278 0.66 LMNA (1.00) LMNAALDH1A1TSHRSMN1; SMN2HSD17B10
Barbital SCHEMBL1650197 0.65 LMNA (0.53) LMNAALDH1A1HSD17B10
Barbital SCHEMBL1650201 0.65 MAPT (0.48) LMNAMAPTALDH1A1NPC1RAB9A
Barbital SCHEMBL23533431 0.64 LMNA (0.94) LMNAALDH1A1TSHRSMN1; SMN2HSD17B10
Barbital SCHEMBL11319317 0.64 LMNA (0.94) LMNAALDH1A1TSHRSMN1; SMN2HSD17B10
Barbital SCHEMBL21084914 0.64 LMNA (0.94) LMNAALDH1A1SMN1; SMN2HSD17B10
Barbital SCHEMBL21084955 0.64 LMNA (0.94) LMNAALDH1A1SMN1; SMN2HSD17B10
Barbital SCHEMBL11328233 0.64 LMNA (0.94) LMNAALDH1A1TSHRSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1608339-B8 PHARMACEUTICAL CO-CRYSTAL OF CELECOXIB-NICOTINAMIDE MCNEIL PPC INC (US) 2012-04-25 — — EP claimed
EP-1608339-A1 PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN Transform Pharmaceuticals, Inc. (US) 2005-12-28 — — EP claimed
WO-2004078161-A1 PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPTINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN TRANSFORM PHARMACEUTICALS, INC. (US) 2004-09-16 — — WO claimed
EP-1631260-A2 PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN Transform Pharmaceuticals, Inc. (US) 2006-03-08 — — EP disclosed
WO-2004078163-A2 PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN TRANSFORM PHARMACEUTICALS, INC. (US) 2004-09-16 — — WO disclosed
Send feedback